Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Elizabeth I. Buchbinder"'
Autor:
Brian R. Gastman, Ahmad A. Tarhini, Robert M. Conry, Pauline Funchain, Karl D. Lewis, Antoni Ribas, Sapna Pradyuman Patel, Hongli Li, Kenneth F. Grossmann, Magdalena Kovacsovics-Bankowski, Teresa M. Petrella, Elizabeth I. Buchbinder, Nageatte Ibrahim, Ragini R. Kudchadkar, James Moon, Douglas B. Johnson, Thach-Giao Truong, Larissa A. Korde, Michael V. Knopp, Kari Kendra, Elad Sharon, Scot Ebbinghaus, Bartosz Chmielowski, Vernon K. Sondak, John M. Kirkwood, Zeynep Eroglu, Nikhil I. Khushalani, Justine V. Cohen, Megan Othus, Krishna S Gunturu, Sama Ahsan
Publikováno v:
Cancer discovery, vol 12, iss 3
Cancer Discov
Cancer Discov
We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be95c3ea01eedee0bb4c9a85fc5d89b2
https://escholarship.org/uc/item/8x51z8rb
https://escholarship.org/uc/item/8x51z8rb
Autor:
Michael Dougan, Elizabeth I. Buchbinder, Meredith Davis, Anita Giobbie-Hurder, William Martin-Doyle, Patrick A. Ott, Osama E. Rahma, Maria Gargano, F. Stephen Hodi, Shilpa Grover, Rawad Elias, Rizwan Haq, Taha Qazi, Kruti Vora, Steven M. Blum, Jeffrey J. Ishizuka, Kevin Tyan, Ryan J. Sullivan, Michael Manos, Lauren Eastman, Alex B. Ruan
Publikováno v:
Cancer
Background There is a lack of predictive markers informing on the risk of colitis in patients treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify potential factors associated with development of ICI colitis. Method
Autor:
Elizabeth I. Buchbinder
Publikováno v:
Hematology/oncology clinics of North America. 35(1)
Immunotherapy with immune checkpoint inhibition has dramatically changed the treatment of melanoma. Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 are approved for the treatment
Autor:
Jonathan D. Schoenfeld, Donald P. Lawrence, Alistair E. W. Johnson, F.S. Hodi, Patrick A. Ott, Elizabeth I. Buchbinder, Rizwan Haq, Ryan J. Sullivan, Peter Bowling, Justine V. Cohen, Michael Manos, Girish S. Naik, Ayal A. Aizer
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 44(8)
Long-term survival outcomes among melanoma patients with brain metastases treated with immune checkpoint inhibitors are limited. In this retrospective study at 2 centers, metastatic melanoma patients with radiographic evidence of brain metastases who
Publikováno v:
Hematology/Oncology Clinics of North America. 33:275-290
The development of immunotherapy to target cancer has led to improved treatment of many types of malignancy. The immune checkpoint inhibitors are a class of medications that block cell signaling and allow the immune system to recognize and attack can
Autor:
Cécile, Gstalder, David, Liu, Diana, Miao, Bart, Lutterbach, Alexander L, DeVine, Chenyu, Lin, Megha, Shettigar, Priya, Pancholi, Elizabeth I, Buchbinder, Scott L, Carter, Michael P, Manos, Vanesa, Rojas-Rudilla, Ryan, Brennick, Evisa, Gjini, Pei-Hsuan, Chen, Ana, Lako, Scott, Rodig, Charles H, Yoon, Gordon J, Freeman, David A, Barbie, F Stephen, Hodi, Wayne, Miles, Eliezer M, Van Allen, Rizwan, Haq
Publikováno v:
Cancer Discov
The molecular mechanisms leading to resistance to PD-1 blockade are largely unknown. Here, we characterize tumor biopsies from a melanoma patient who displayed heterogeneous responses to anti-PD-1 therapy. We observe that a resistant tumor exhibited
Autor:
Douglas B, Johnson, Wyatt J, McDonnell, Paula I, Gonzalez-Ericsson, Rami N, Al-Rohil, Bret C, Mobley, Joe-Elie, Salem, Daniel Y, Wang, Violeta, Sanchez, Yu, Wang, Cody A, Chastain, Kristi, Barker, Yan, Liang, Sarah, Warren, Joseph M, Beechem, Alexander M, Menzies, Martin, Tio, Georgina V, Long, Justine V, Cohen, Amanda C, Guidon, Méabh, O'Hare, Sunandana, Chandra, Akansha, Chowdhary, Bénédicte, Lebrun-Vignes, Simone M, Goldinger, Elisabeth J, Rushing, Elizabeth I, Buchbinder, Simon A, Mallal, Chanjuan, Shi, Yaomin, Xu, Javid J, Moslehi, Melinda E, Sanders, Jeffrey A, Sosman, Justin M, Balko
Publikováno v:
Nature medicine
Checkpoint inhibitors produce durable responses in numerous metastatic cancers, but immune-related adverse events (irAEs) complicate and limit their benefit. IrAEs can affect organ systems idiosyncratically; presentations range from mild and self-lim
Autor:
David F. McDermott, Sapna Pradyuman Patel, Gerald P Miletello, Brendan D. Curti, Ann W. Silk, Janice P. Dutcher, Rene Gonzalez, Mayer Fishman, Scott S. Tykodi, Elizabeth I. Buchbinder, Joseph I. Clark, Gregory A. Daniels, Shernan G. Holtan, Christopher D. Lao, John M. Richart
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Background Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can lead to durable responses in
Autor:
F. Stephen Hodi, Jason J. Luke, Elizabeth I. Buchbinder, Paul Leger, Richard W. Joseph, Fei Ye, Daniel Y. Wang, Rizwan Haq, Jeffrey A. Sosman, Zeynep Eroglu, Alpaslan Özgün, Shilin Zhao, Douglas B. Johnson, Patrick A. Ott
Anti–PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti–PD-1. We retrospectively reviewed 488 patients treated with anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31445cdc384b37272d7330b860af374c
https://europepmc.org/articles/PMC5502536/
https://europepmc.org/articles/PMC5502536/
Autor:
Luke R.G. Pike, Monica Krishnan, Alexander Spektor, Brian M. Alexander, Andrew Bang, F. Stephen Hodi, Patrick A. Ott, Paul J. Catalano, Allison Taylor, Mark M. Awad, Tracy A. Balboni, Bhupendra Rawal, Ayal A. Aizer, Daniel N. Cagney, Elizabeth I. Buchbinder, Leena Gandhi, Jonathan D. Schoenfeld
Publikováno v:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 124(1)
Background and purpose Patients with metastatic melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) are increasingly treated with immune checkpoint blockade targeting the programed death (PD)-1 receptor, often with palliative